Literature DB >> 24778401

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.

Douglas B Johnson1, Vita Saranga-Perry2, Patrick J M Lavin3, W Bryan Burnette3, Stephen W Clark3, David R Uskavitch3, Deborah E Wallace3, Mark A Dickson4, Ragini R Kudchadkar2, Jeffrey A Sosman3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24778401      PMCID： PMC4979104          DOI： 10.1200/JCO.2013.51.1683

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  24 in total

Review 1.  Statin-associated myasthenia gravis: report of 4 cases and review of the literature.

Authors:  Valerie Purvin; Aki Kawasaki; Kyle H Smith; Anat Kesler
Journal:  Medicine (Baltimore)       Date:  2006-03       Impact factor: 1.889

2.  Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.

Authors:  S Wilgenhof; B Neyns
Journal:  Ann Oncol       Date:  2011-02-28       Impact factor: 32.976

Review 3.  Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors:  Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

4.  Guidelines for treatment of autoimmune neuromuscular transmission disorders.

Authors:  G O Skeie; S Apostolski; A Evoli; N E Gilhus; I Illa; L Harms; D Hilton-Jones; A Melms; J Verschuuren; H W Horge
Journal:  Eur J Neurol       Date:  2010-04-12       Impact factor: 6.089

5.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

6.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

7.  A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.

Authors:  Caroline Gaudy-Marqueste; Sandrine Monestier; Jérome Franques; Emmanuel Cantais; Marie-Aleth Richard; Jean-Jacques Grob
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

8.  Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis.

Authors:  Ming Gu; Maria Kakoulidou; Ricardo Giscombe; Ritva Pirskanen; Ann Kari Lefvert; Lars Klareskog; XiongBiao Wang
Journal:  Clin Immunol       Date:  2008-07-02       Impact factor: 3.969

9.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Authors:  I Elovaara; S Apostolski; P van Doorn; N E Gilhus; A Hietaharju; J Honkaniemi; I N van Schaik; N Scolding; P Soelberg Sørensen; B Udd
Journal:  Eur J Neurol       Date:  2008-09       Impact factor: 6.089

10.  Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis.

Authors:  Q Yi; R Pirskanen; A K Lefvert
Journal:  J Neuroimmunol       Date:  1993-02       Impact factor: 3.478
View more
  32 in total

1.  Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.

Authors:  Henry T Quach; Charles J Robbins; Justin M Balko; Charles Y Chiu; Steve Miller; Michael R Wilson; George E Nelson; Douglas B Johnson
Journal:  Oncologist       Date:  2019-04-01

Review 2.  Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.

Authors:  Dustin Anderson; Grayson Beecher; Nabeela Nathoo; Michael Smylie; Jennifer A McCombe; John Walker; Rajive Jassal
Journal:  Neurooncol Pract       Date:  2018-10-04

Review 3.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 4.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

Review 5.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.

Authors:  Peter Chei-Way Pan; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2019-11-27       Impact factor: 5.075

Review 6.  Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Authors:  Shannon K Quirk; Anna K Shure; Devendra K Agrawal
Journal:  Transl Res       Date:  2015-06-11       Impact factor: 7.012

Review 7.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

Review 8.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081

Review 9.  Neuro-ophthalmic side effects of molecularly targeted cancer drugs.

Authors:  M T Bhatti; A K S Salama
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.